Myelodysplastic syndromes, pilot register,first results. Grupo de Estudio de Síndromes Mielodisplásticos. Sociedad Argentina de Hematología

PRATES, M VIRGINIA; ARBELBIDE, JORGE; SACKMAN, FEDERICO; CAMPESTRI, REINALDO; SANTOS, I; IASTREBNER, MARCELO; FLORES, GABRIELA; AGRA, MARCELA; CABREJO, M; RIVAS, M MARTA; BELLI, CAROLINA; VENTRIGLIA, M; FAZIO, P; CAICEDO, LAURA

Patras

Simposio; 10th International Symposium on Myelodysplastic Syndromes; 2009

Myelodysplastic Fundation

Introduction: Little is known about the incidence and epidemiological patterns of Myelodysplastic Syndromes (MDS) in Latin American region. The requirement of a high quality exchangeable data has become a priority all over the world.Little is known about the incidence and epidemiological patterns of Myelodysplastic Syndromes (MDS) in Latin American region. The requirement of a high quality exchangeable data has become a priority all over the world. Objective: To register MDS cases reported in our region, to review and analyze the data.To register MDS cases reported in our region, to review and analyze the data. Methods: From January 2007 through August 2008 fourteen Argentine Hematology Centers completed the report prepared ad-hoc of 132 patients.We included patients according to Valent et al. MDS criteria (Leuk Res, 2007).From January 2007 through August 2008 fourteen Argentine Hematology Centers completed the report prepared ad-hoc of 132 patients.We included patients according to Valent et al. MDS criteria (Leuk Res, 2007).Leuk Res, 2007). Results: The median age was 74 years old, male 55%, primary MDS 92% and secondary MDS 8%. We analyzed 122 primary MDS patients and 16 CMML, 2 AML/MDS (RAEB-T by FAB) were excluded, based on WHO classification.The median age was 74 years old, male 55%, primary MDS 92% and secondary MDS 8%. We analyzed 122 primary MDS patients and 16 CMML, 2 AML/MDS (RAEB-T by FAB) were excluded, based on WHO classification. FAB: 122 patients with primary MDS AR ARSA ARE-B AREB-T LMMC NE 45.1% 7.4% 16.4% 5.7% 13.1% 12.3% WHO: 106 patients with primary MDS AR ARSA CRDM CRDM-SA AREB 1 AREB 2 del(5q)- associated 22.1% 5.7% 32% 1.6% 5.7% 15.6% 0.8% Cytogenetic study was performed in 87% of patients and karyotype abnormalities were found in 70% of secondary and in 27% of primary MDS (p=0.01). Bone marrow flow cytometry study was performed in 66% of patients; however, there is no consensus on how these results should be analyzed. One hundred and one patients where classified according to the IPSS: Low Risk 42%, INT-1 40%, INT-2 11%, High Risk 8% and Non-Evaluable 21%. There was a close correlation between High IPSS score and the probability to develop acute myeloidp=0.01). Bone marrow flow cytometry study was performed in 66% of patients; however, there is no consensus on how these results should be analyzed. One hundred and one patients where classified according to the IPSS: Low Risk 42%, INT-1 40%, INT-2 11%, High Risk 8% and Non-Evaluable 21%. There was a close correlation between High IPSS score and the probability to develop acute myeloid leukemia (p>0.001), mortality (p>0.001), transfusion load (p = 0.02) and chemotherapy requirement (p = 0.02) or hypomethylating agents treatment (p = 0.04).>0.001), mortality (p>0.001), transfusion load (p = 0.02) and chemotherapy requirement (p = 0.02) or hypomethylating agents treatment (p = 0.04). Conclusion: This study is the base of a National MDS Register; however, further data is still needed in order to get a better knowledge of the disease in Argentina.This study is the base of a National MDS Register; however, further data is still needed in order to get a better knowledge of the disease in Argentina.